ARTIDIS Gains Strong Momentum in 2019 Raising CHF 8.8 Million in Seed Financing

ARTIDIS AG (“ARTIDIS”), a privately held healthtech company, announced the successful closure of a CHF 8.8 million seed financing in two rounds securing early clinical validation and the next development phase towards market entry in 2021.

The funding will be used to advance the company’s healthtech platform into a large multi-centre clinical study together with the University Hospital Tuebingen (Germany), University Hospital Barcelona (Spain), and Texas Medical Center (Houston, US). The study aims to further validate the value of ARTIDIS in diagnosing breast and lung cancer, as well as for personalizing and optimizing cancer treatment. The results will support the regulatory submissions to the FDA and the European Notified Body to gain approval for the ARTIDIS medical device and data platform. This is one of the major prerequisites for ARTIDIS to enter the diagnostic market world-wide in 2021 in order to improve the standard of care for cancer patients.

Media release ARTIDIS